The maker of an at-home cervical cancer screening test said Friday it has won approval from the Food and Drug Administration, giving patients an alternative to in-clinic pap smears.

Novavax is undervalued, presenting an attractive risk-reward profile for long-term investors. Click here to find out why NVAX ...